1 / 16

Regulatory Issues Related to Crystal Habits - Polymorphism

Regulatory Issues Related to Crystal Habits - Polymorphism. 1:45 - 2:00 Polymorphs - What’s the Problem? Gary Buehler, R. Ph., Director, OGD, FDA 2:00 - 2:30 Scientific Considerations of Polymorphism in ANDAs. Lawrence X. Yu, Ph. D., Director for Science, OGD, FDA

kane
Télécharger la présentation

Regulatory Issues Related to Crystal Habits - Polymorphism

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Regulatory Issues Related to Crystal Habits - Polymorphism 1:45 - 2:00 Polymorphs - What’s the Problem? Gary Buehler, R. Ph., Director, OGD, FDA 2:00 - 2:30 Scientific Considerations of Polymorphism in ANDAs. Lawrence X. Yu, Ph. D., Director for Science, OGD, FDA 2:30 - 3:00 Expert Comments, 30 minutes Kenneth R. Morris, Ph. D., Purdue University Harry G. Brittain, Ph. D., Center for Pharmaceutical Physics Leslie Benet, Ph. D., University of California 3:30 - 4:45 Q & A CDER/Office of Generic Drugs

  2. Advisory Committee for Pharmaceutical Science Polymorphs - What’s the problem? Gary J. Buehler, R.Ph. Director, Office of Generic Drugs October 21, 2002

  3. Polymorphs The same...but...maybe different CDER/Office of Generic Drugs

  4. Same active ingredient: Carbon • Coal cannot be generically substituted for a diamond unless ANDA applicants show that • Coal is bioequivalent to a diamond • Coal exhibits the same identity, strength, purity, quality, and stability CDER/Office of Generic Drugs

  5. Polymorphs/Formulations Not Bioequivalent Crystalline Sugar Bioequivalent Powdered Sugar Intestinal Membrane CDER/Office of Generic Drugs

  6. “Same” Requirement • 314.94(a)(5) states, …the active ingredient is the same as that of the reference listed drug… CDER/Office of Generic Drugs

  7. “Same” Requirement • Regulation Preamble clarifies the definition of “same” • Meets the same standards for identity as described in USP • In some cases, however, FDA may prescribe additional standards, i.e., crystalline structure or stereoisomeric mixture • Questions should be directed to OGD CDER/Office of Generic Drugs

  8. What is Polymorphism? • Different physical forms of the same chemical structure • Different polymorphs may exhibit different properties, including stability and bioavailability CDER/Office of Generic Drugs

  9. Polymorph Proliferation • With modern technology, the identification of multiple polymorphs has become easier • Because of their unacceptable properties however, the majority of these polymorphs have little utility and cannot be developed into quality products CDER/Office of Generic Drugs

  10. History • Cefuroxime Axetil • Sept 29, 2000 Citizen Petition filed on behalf of GlaxoSmithKline (GSK) • Requested that FDA deny approval of any ANDA for a Cefuroxime Axetil product whose active ingredient is wholly or partially in crystalline form • Or, require stringent drug substance and drug product specifications for solid-state form (including content of individual polymorphs) CDER/Office of Generic Drugs

  11. History • Cefuroxime Axetil • Involved USP monograph petition • Result was a 37-page response that detailed our own scientific position on polymorphs • Response is in the public record - Petition Number: 00P-1550/CP1 & PSA1 01P-0428/CP1 & PSA1 CDER/Office of Generic Drugs

  12. History • Omeprazole • About 4 months before the pediatric exclusivity for Prilosec was due to expire, we were informed of a possible polymorph issue • After significant review of the available data, the issue was addressed CDER/Office of Generic Drugs

  13. History • Fluoxetine • On July 18, 2001, about two weeks before the pediatric exclusivity for Prozac was due to expire, we were informed that aaiPharma held a patent on one polymorphic form of fluoxetine • They asserted that their patent claimed the drug product or method of using Prozac and should be listed in the Orange Book • Only the NDA sponsor however, is authorized to request a patent listing CDER/Office of Generic Drugs

  14. History • Fluoxetine • Eli Lilly, the NDA applicant for Prozac, informed aaiPharma that they did not plan on listing the patent in the Orange Book • aaiPharma appealed to FDA • FDA contacted Eli Lilly and asked for a confirmation of their decision • Lilly replied to FDA that it was not listing the patent • aaiPharma then asked FDA to list the patent CDER/Office of Generic Drugs

  15. History • Fluoxetine • FDA replied that only the NDA applicant can list patents for its product in the Orange Book • aaiPharma sued the FDA • aaiPharma lost the lawsuit and the appeal CDER/Office of Generic Drugs

  16. Summary • An ANDA applicant is required to demonstrate that their proposed product meets the standards for identity, exhibits acceptable stability, and is bioequivalent to the reference listed drug. CDER/Office of Generic Drugs

More Related